

Under the Paperwork Reduction Project
Substitute for form 1449/PTO

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/824,027
Filing Date	April 14, 2004
First Named Inventor	VAN EYK, Jennifer E.
Art Unit	1653
Examiner Name	
Attorney Docket Number	PTQ-0058

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ² Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY			
AK	1	WO 03/004693 A2	Jan 16, 2003	Queen's University at Kingston		

**Examiner
Signature**

Date Considered

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). (*See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/089 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1-499-PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/824,027
Filing Date	April 14, 2004
First Named Inventor	VAN EYK, Jennifer E.
Art Unit	1653
Examiner Name	
Attorney Docket Number	PTQ-0058

Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AP	1	ALA-RAMI, A., et al. "Ischaemic preconditioning and a mitochondrial KATP channel opener both produce cardioprotection accompanied by F1FO-ATPase inhibition in early ischaemia." Basic Res. Cardiol. 98: 250 - 258 (2003).	
AP	2	BOLLI, R. "The late phase of preconditioning." Circ. Res. 87: 972 - 983 (2000).	
AP	3	DANA, A., et al. "Adenosine A1 receptor induced delayed preconditioning in rabbits. Induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism." Circ. Res. 86: 989 - 997 (2000).	
AP	4	HANLEY, P.J., et al. "Halothane, isoflurane and sevoflurane inhibit NADH: ubiquinone oxidoreductase (complex I) of cardiac mitochondria." J. Physiol. 544.3: 687 - 693 (2002).	
AP	5	KLONER, R.A., et al. "Consequences of brief ischemia: stunning, preconditioning, and their clinical implications." Circulation 104: 2981 - 2989 (2001).	
AP	6	SCHAFER, G., et al. "Diazoxide, an inhibitor of succinate oxidation." Biochem. Pharma. 18: 2678 - 2681 (1969).	
AP	7	SCHAFER, G., et al. "Inhibition of mitochondrial metabolism by the diabetogenic thiazidine diazoxide - I. Action on succinate dehydrogenase and TCA-cycle oxidations." Biochem. Pharma. 20: 1271 - 1280 (1971).	
AP	8	THORNTON, J., et al. "Inhibition of protein synthesis does not block myocardial protection afforded by preconditioning." Am. J. Physiol. 259: H1822 - H1825 (1990).	


Examiner Signature		Date Considered	5/10/05
--------------------	--	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Sheet 01 of 01

Patent No. 10-1449 Modified		Docket No. PTQ-0058	Serial No. 10/824,027
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Van Eyk et al.	
		Filing Date April 14, 2004	Group 1653
U.S. Department of Commerce			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
AD	AA	Hanley et al., "K _{ATP} channel-independent targets of diazoxide and 5-hydroxydecanoate in the heart", Journal of Physiology 2002 542.3:735-741	
	AB	Hanley et al., "Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria", Journal of Physiology 2002 544.3:687-693	
EXAMINER	DATE CONSIDERED		5/10/05

on 12/29/04
IOS.